Ulcerative Colitis

Ulcerative colitis is a common inflammatory disease of the colon characterized by inflammation and ulceration of the large bowel and rectum. The condition impairs the ability of the large bowel to absorb water which results in diarrhea, the main symptom of the condition.

Ulcerative colitis is a relapsing and remitting condition, meaning symptoms can die down for long periods but then flare-up from time to time. These flare-ups can be sudden and severe. During a period of relapse, symptoms may include bloody diarrhea, abdominal pain and a sudden urge to defecate. Other symptoms include wind, loss of appetite, weight loss, fever and fatigue.

Currently, there is no cure for the condition apart from surgery. However, certain treatments such as corticosteroids or immunosuppressants may be used to ease symptoms by reducing inflammation. Surgery for severe ulcerative colitis that does not respond to treatment involves completely removing the large bowel and re-routing the small bowel so that waste can still be expelled. This procedure is called a colectomy.

In the UK, the incidence of ulcerative colitis is around 1 in 500 and the condition is equally common among males and females. Symptoms can develop at any age, but onset usually occurs between 15 and 30 years of age.

How GLP-1 Drugs May Affect Crohn’s Disease and Ulcerative Colitis

GLP-1 receptor agonists support weight loss and metabolic control in people with inflammatory bowel disease, while preclinical studies suggest possible anti-inflammatory effects. Observational studies associate their use with fewer adverse IBD outcomes in some populations, but randomized trials are needed to establish clinical benefits.

Ulcerative Colitis Causes

Ulcerative Colitis Research

What is Ulcerative Colitis?

Ulcerative Colitis Epidemiology

Ulcerative Colitis Treatment

Ulcerative Colitis Diagnosis

Latest Ulcerative Colitis News and Research

Ulcerative colitis burden across 7MM to exceed 2.36 million cases by 2035, forecasts GlobalData

The diagnosed prevalent cases of ulcerative colitis (UC) in the seven major markets (7MM) are projected to reach over 2.36 million by 2035.

28 Oct 2026

UK study identifies ways to improve bowel cancer detection in IBD patients

The first UK-wide analysis of bowel screening for patients with inflammatory bowel disease (IBD) has identified opportunities to improve the early detection of cancer.

27 Oct 2026

Antibody patterns may predict inflammatory bowel disease years before diagnosis

A large-scale study, presented today at UEG Week 2026, has identified distinct antibody patterns up to 10 years before the diagnosis of inflammatory bowel disease (IBD), potentially opening new avenues for earlier risk detection and providing insights into future disease course.

19 Oct 2026

Gut inflammation may explain food sensitivities in IBD patients

A new study, to be published in Gastroenterology, finds that gut inflammation can change the way gut bacteria break down food - possibly triggering immune reactions to foods that were previously fine to eat.

7 Oct 2026

New study investigates PFAS exposure and future inflammatory bowel disease

Exposure to per- and polyfluoroalkyl substances (PFAS), often called "forever chemicals," may play a role in the development of inflammatory bowel disease (IBD) years before symptoms appear, according to a new five-year study supported by a $3.3 million National Institutes of Health (NIH) R01 grant to researchers at the Icahn School of Medicine at Mount Sinai.

5 Oct 2026

Garvan research reveals hidden inflammation behind high colon cancer risk

New research from the Garvan Institute of Medical Research has revealed for the first time that two closely related bowel diseases, currently treated in the same way, are fundamentally different.

22 Sep 2026

IBD patients with family cancer history more likely to develop colorectal cancer

People with inflammatory bowel disease (IBD) who have several close relatives with colorectal cancer are significantly more likely to develop the disease themselves.

3 Sep 2026

Antifungal medication may reduce inflammatory bowel disease symptoms

A commonly used systemic antifungal medication may help reduce symptoms in a subset of patients with inflammatory bowel disease (IBD) by restoring a healthier gut microbiome, according to a preliminary study by Weill Cornell Medicine investigators.

1 Sep 2026

Researchers identify early molecular warning signs of inflammatory bowel disease

Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin before symptoms appear and continue silently even when patients appear well.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 29 Aug 2026

Polydatin reduces ulcerative colitis by regulating intestinal immune cells

Ulcerative colitis (UC) is a chronic inflammatory bowel disease in which recurrent intestinal inflammation can be difficult to control over the long term.

17 Aug 2026

Inflammatory bowel disease linked to elevated risk of psychiatric disorders

Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade after, according to a nationwide study to be published in Clinical Gastroenterology and Hepatology.

5 Aug 2026

Global childhood IBD trends reveal unequal progress in diagnosis and survival

An analysis of GBD 2021 estimates across 204 countries and territories found that global deaths from early-onset IBD fell by approximately 71% among children younger than 10 between 1990 and 2021. However, estimated incident and prevalent case numbers rose while the age-standardized incidence rate remained broadly stable, with persistent socioeconomic and regional inequalities.

20 Jul 2026

Researchers identify key protein balancing gut immunity and inflammation

A protein produced by gut immune cells orchestrates both immune protection against pathogens and immune tolerance of gut bacteria, according to a study led by Weill Cornell Medicine investigators.

7 Jul 2026

New project investigates gut microbiome for personalized bowel disease therapies

The gut microbiome plays an important role in inflammatory bowel disease. In the research project MikrobiomProCheck, researchers are investigating how microbiome data can in future be used for diagnostics, disease monitoring and personalized therapies.

26 Jun 2026

Using blood proteomics to identify pediatric inflammatory bowel disease risk

For children with suspected inflammatory bowel disease (IBD), a chronic, relapsing condition of the gastrointestinal tract, getting the right diagnosis relies on a combination of clinical evaluation, imaging, endoscopy, and histopathology.

24 Jun 2026

Natural microbial compound helps protect the gut from chronic inflammation

University of Louisville researchers have discovered how a naturally occurring microbial compound may help protect the gut and support future treatment strategies for inflammatory bowel disease (IBD).

24 Jun 2026

Researchers advocate local data strategies for early cancer detection

Researchers are calling for the application of locally driven strategies, supported by stronger regional evidence, to improve early cancer detection and precise care.

22 Jun 2026

Study identifies genetic marker associated with severe IBD

In the largest genetic study of inflammatory bowel disease (IBD) traits to date, researchers have identified a genetic marker that is associated with more severe ulcerative colitis and Crohn's disease – the major forms of IBD.

15 Jun 2026

Study identifies an important driver of inflammatory bowel disease

Researchers at the Nuffield Department of Medicine, University of Oxford, together with Newcastle University's Translational and Clinical Research Institute and the Department of Immunology at Cambridge University Hospitals NHS Foundation Trust, have identified an important driver of inflammatory bowel disease (IBD).

10 Jun 2026

Genetically-modified hookworms successfully deliver medicine to animal hosts

Hookworms, intestinal parasites that infect hundreds of millions of people in under-resourced tropical regions around the globe, have evolved to survive inside the human gut for years, secreting molecules that enable co-existence with their hosts.

3 Jun 2026